Omar Ali, MD
Interventional Cardiology · Winchester, VANPI 1972527059
Payments from drug & device makers
What this record shows
Abbott accounts for 66.6% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2019 at $2,762 and has fallen 81.2% since, to $520 in 2025.
Across 116 payments — averaging $56.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$4K
- Medtronic$672
- Boston Scientific$450
- Edwards Lifesciences$178
- Abiomed$146
- Livanova USA, Inc.$142
- plus $597 from 12 others
Across 10 payments — averaging $11,911 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$119K
What the payments were for
- Travel & lodging$2,70641%
- Food & beverage$3,83059%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 41 | $4,351 |
| Medtronic(2 entities) | 17 | $672 |
| Boston Scientific | 14 | $450 |
| Edwards Lifesciences | 4 | $178 |
| Abiomed | 1 | $146 |
| Livanova USA, Inc. | 1 | $142 |
| AstraZeneca | 8 | $111 |
| Johnson & Johnson | 5 | $104 |
| Amgen | 6 | $90 |
| Novartis | 5 | $75 |
| Pfizer | 4 | $61 |
| Amarin Pharma, Inc. | 2 | $45 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $31 |
| E.r. Squibb & Sons, L.L.C. | 2 | $26 |
| Cardiovascular Systems Inc. | 1 | $15 |
| Vifor Pharma, Inc. | 1 | $14 |
| Tactile Systems Technology Inc | 1 | $14 |
| Dentsply Sirona Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Mitra Clip system$1,459
- MitraClip$280
- Watchman$226
- COREVALVE EVOLUT R$163
- Impella$146
- Perceval$142
How this compares
$6,536 in reported general payments places this provider in the 55th percentile of 176 interventional cardiology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 238 | $270,944 |
| EntrestoSacubitril/Valsartan | 54 | $81,187 |
| Repatha SureclickEvolocumab | 90 | $80,415 |
| XareltoRivaroxaban | 40 | $48,017 |
| Rosuvastatin Calcium | 902 | $19,589 |
| ClopidogrelClopidogrel Bisulfate | 428 | $7,799 |
| Metoprolol Succinate | 239 | $4,554 |
| Bisoprolol Fumarate | 139 | $4,053 |
| Atorvastatin Calcium | 238 | $3,756 |
| Prasugrel Hcl | 61 | $3,625 |
| Ranolazine ErRanolazine | 25 | $2,437 |
| Carvedilol | 146 | $2,095 |
| Ezetimibe | 93 | $1,505 |
| Pantoprazole Sodium | 96 | $1,493 |
| FenofibrateFenofibrate Nanocrystallized | 69 | $1,460 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $61 | $270,944238 claims |
| NovartisEntresto | $75 | $81,18754 claims |
| Johnson & JohnsonXarelto | $104 | $48,01740 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 176 interventional cardiology providers in Virginia.
Other interventional cardiology in Winchester
- Ajay VirmaniWinchester$19K
- Deepak TalrejaVirginia Beach$1.5M
- Rajiv TayalFredericksburg$984K
- Gansevoort DunningtonRichmond$440K
- Matthew SummersNorfolk$308K
- Noah JonesFalls Church$238K
- Michael GenVirginia Beach$207K
- Jeremy BockLeesburg$202K
- Wayne BatchelorFalls Church$196K
- Matthew SherwoodFalls Church$193K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.